During the past two decades, there have been numerous attempts at using animals in order
to produce recombinant human proteins and monoclonal antibodies. However, it is only …

Recombinant blood clotting factor VIII is one of the most complex proteins for industrial
manufacturing due to the low efficiency of its gene transcription, massive intracellular loss of …

The posttranslational modification of therapeutic proteins with terminal sialic acids is one
means of improving their circulating half-life, thereby improving their efficiency. We have …

N-glycosylation is a process during which a glycan moiety attaches to the asparagine
residue in the N-glycosylation consensus sequence (Asn-Xxx-Ser/Thr), where Xxx can be …

Hemophilia B is an X-linked genetic deficiency of coagulation factor IX (FIX) activity
associated with recurrent deep tissue and joint bleeding that may lead to long-term …

Appropriate glycosylation of recombinant therapeutic glycoproteins has been emphasized in
biopharmaceutical industries because the carbohydrate component can affect safety …

Coagulation factor IX (FIX) is a complex post-translationally modified human serum
glycoprotein and high-value biopharmaceutical. The quality of recombinant FIX (rFIX) …

Factor IX is a zymogen enzyme of the blood coagulation cascade. Inherited absence or
deficit of the IX functional factor causes bleeding disorder hemophilia B, which requires …

Background Thromboses is a rapidly growing medical problem worldwide. Low-cost, high-
scale production of thrombotic drugs is needed to meet the demand. The production of …

Background: Current manufacturing methods for recombinant human factor VIII (rFVIII) within
mammalian cell cultures are inefficient, hampering the production of sufficient amounts for …